Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Nab-paclitaxel plus cisplatin weekly concurrent chemoradiotherapy for limited-stage cervical cancer
ChiCTR2000034251Phase 2Not yet recruiting
- Sponsor
- Inner Mongolia Autonomous Region People's Hospital
- Start
- Aug 2020
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of paclitaxel and cisplatin in Cervical Cancer (CC), sponsored by Inner Mongolia Autonomous Region People's Hospital. Primary endpoints: Objective Response Rate and Safety and Tolerability. Planned start Aug 2020; status: not yet recruiting.
02
Drugs
paclitaxelcisplatin
03
Conditions
Cervical Cancer (CC)
Beyond the preview
Go deeper on ChiCTR2000034251.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2000034251.